SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
See full prescribing information for complete boxed warning.
- TRADE NAME: Erbitux (Bristol-Myers Squibb)
- INDICATIONS: Metastatic colorectal cancer, squamous cell carcinoma of the head and neck
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Monoclonal antibody
- HALF-LIFE: 75–188 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Epidermal growth factor receptor (EGFR) inhibitor / antagonist
Please login to view the rest of this drug profile.
Page last updated 04/02/2024
